Pfizer Inc. (PFE) Downgraded by Vetr Inc. to Buy
Vetr lowered shares of Pfizer Inc. (NYSE:PFE) from a strong-buy rating to a buy rating in a report published on Thursday. They currently have $36.36 price objective on the biopharmaceutical company’s stock.
Other research analysts have also issued reports about the stock. Argus restated a buy rating and issued a $39.00 price objective on shares of Pfizer in a report on Sunday, August 28th. Jefferies Group lowered shares of Pfizer from a buy rating to a hold rating and decreased their price objective for the stock from $39.00 to $36.00 in a report on Thursday. Sanford C. Bernstein restated an outperform rating on shares of Pfizer in a report on Monday, September 26th. Citigroup Inc. restated a neutral rating and issued a $37.00 price objective on shares of Pfizer in a report on Wednesday, August 3rd. Finally, Barclays PLC restated an equal weight rating and issued a $34.00 price objective on shares of Pfizer in a report on Tuesday, August 2nd. Eleven investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of Buy and a consensus price target of $38.59.
Pfizer (NYSE:PFE) traded up 0.31% on Thursday, reaching $32.86. 2,601,781 shares of the company traded hands. The stock’s 50 day moving average price is $34.08 and its 200 day moving average price is $34.25. Pfizer has a one year low of $28.25 and a one year high of $37.39. The company has a market capitalization of $199.32 billion, a PE ratio of 29.13 and a beta of 0.86.
Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.62 by $0.02. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The business earned $13.10 billion during the quarter, compared to analyst estimates of $13.01 billion. During the same period in the prior year, the business earned $0.56 EPS. The company’s revenue for the quarter was up 10.9% on a year-over-year basis. On average, equities research analysts predict that Pfizer will post $2.46 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 1st. Investors of record on Friday, November 11th will be issued a $0.30 dividend. The ex-dividend date is Tuesday, November 8th. This represents a $1.20 annualized dividend and a dividend yield of 3.66%. Pfizer’s payout ratio is currently 95.24%.
Several hedge funds have recently added to or reduced their stakes in PFE. Bloom Tree Partners LLC purchased a new stake in Pfizer during the first quarter valued at $35,682,000. State of Alaska Department of Revenue increased its position in shares of Pfizer by 11.3% in the second quarter. State of Alaska Department of Revenue now owns 371,887 shares of the biopharmaceutical company’s stock worth $13,093,000 after buying an additional 37,647 shares in the last quarter. BlackRock Group LTD increased its position in shares of Pfizer by 5.6% in the first quarter. BlackRock Group LTD now owns 59,474,971 shares of the biopharmaceutical company’s stock worth $1,762,838,000 after buying an additional 3,154,116 shares in the last quarter. Charter Trust Co. increased its position in shares of Pfizer by 4.3% in the second quarter. Charter Trust Co. now owns 377,918 shares of the biopharmaceutical company’s stock worth $13,306,000 after buying an additional 15,510 shares in the last quarter. Finally, Franklin Resources Inc. increased its position in shares of Pfizer by 16.7% in the first quarter. Franklin Resources Inc. now owns 62,902,993 shares of the biopharmaceutical company’s stock worth $1,864,446,000 after buying an additional 9,005,107 shares in the last quarter. Hedge funds and other institutional investors own 69.66% of the company’s stock.
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.